SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity…
SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity…
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading…
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading…
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…